BeiGene, Ltd. Cash Flow Conversion Efficiency
BeiGene, Ltd. cash flow conversion efficiency. Based on the latest financial reports, BeiGene, Ltd. (ONC) has a cash flow conversion efficiency ratio of 0.042x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($201.94 Million) by net assets ($4.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BeiGene, Ltd. (2013–2025)
Cash flow conversion efficiency of BeiGene, Ltd. from 2013 to 2025. This chart illustrates how BeiGene, Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for BeiGene, Ltd. for real-time trading data and today's change.
BeiGene, Ltd. Cash Flow Conversion Ratio Explained
BeiGene, Ltd. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BeiGene, Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeiGene, Ltd. ranked by their cash flow conversion efficiency. Also see BeiGene, Ltd. (ONC) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Martin Marietta Materials Inc
NYSE:MLM
|
0.010x |
|
SANDVIK AB SP.ADR
F:SVK
|
0.046x |
|
Banco Bradesco DRC
BA:BBD
|
0.005x |
|
Svenska Handelsbanken AB (publ)
ST:SHB-A
|
0.330x |
|
ABN Amro Group NV
AS:ABN
|
0.010x |
|
EQT Corporation
NYSE:EQT
|
0.036x |
|
Muyuan Foodstuff Co Ltd
SHE:002714
|
0.015x |
|
Biogen Inc
NASDAQ:BIIB
|
0.024x |
Annual Cash Flow Conversion Efficiency for BeiGene, Ltd. (2013–2025)
The table below shows the annual cash flow conversion efficiency of BeiGene, Ltd. from 2013 to 2025. Review BeiGene, Ltd. (ONC) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.36 Billion | $1.13 Billion | 0.259x | +712.63% |
| 2024-12-31 | $3.33 Billion | $-140.63 Million | -0.042x | +87.10% |
| 2023-12-31 | $3.54 Billion | $-1.16 Billion | -0.327x | +4.17% |
| 2022-12-31 | $4.38 Billion | $-1.50 Billion | -0.341x | -61.22% |
| 2021-12-31 | $6.13 Billion | $-1.30 Billion | -0.212x | +36.16% |
| 2020-12-31 | $3.87 Billion | $-1.28 Billion | -0.332x | +56.75% |
| 2019-12-31 | $978.36 Million | $-750.27 Million | -0.767x | -145.53% |
| 2018-12-31 | $1.75 Billion | $-547.72 Million | -0.312x | -1775.86% |
| 2017-12-31 | $684.23 Million | $12.75 Million | 0.019x | +107.35% |
| 2016-12-31 | $352.91 Million | $-89.51 Million | -0.254x | +52.69% |
| 2015-12-31 | $74.32 Million | $-39.84 Million | -0.536x | -58.90% |
| 2014-12-31 | $25.77 Million | $-8.69 Million | -0.337x | -206.16% |
| 2013-12-31 | $-36.96 Million | $4.07 Million | -0.110x | -- |
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more